Novel high‐affinity EGFRvIII‐specific chimeric antigen receptor T cells effectively eliminate human glioblastoma

Le résumé fourni par la source

Clinical & Translational Immunology 2021; 10: e1317. Correction to: Clin Trans Immunol 2021; 10: e1283. https://doi.org/10.1002/cti2.1283. Published online 9 May 2021 Figure 5 originally published in this article was incorrect, as it contained a duplicated mouse image. The corrected Figure 5 and its caption appear below. GCT02 CAR T cells effectively induce regression of intracranial tumors. (a) Schematic of the experimental protocol to evaluate the in vivo function of CAR T cells against EGFRvIII-expressing intracranial tumors. Mice were intracranially injected with U87-EGFRvIII GFP-Luc tumor cells and 7 days later were imaged using bioluminescence. The mice were allocated to treatment groups before delivery of a single intravenous dose of 5 × 106 CD4+: 5 × 106 CD8+ T cells day 8 post-activation GCT02 or C2173 CAR T cells. Empty vector T cells (EV) were injected as a negative control. Bioluminescence was examined weekly to monitor tumor size over time. The tumor injection site is indicated by black circle. (b) Bioluminescence imaging of U87-EGFRvIII GFP-Luc tumor-bearing NSG mice, treated with either empty vector (EV), C2173 or GCT02 CAR T cells. Individual mice from each treatment group are shown for up to 3 weeks after CAR T cell infusion. Representative of two independent experiments. (c) Quantification of tumor growth in the mice in panel b. Tumor size was quantitated in radiance (photons/sec/area/sr). Each line represents a single mouse. n = 5 mice per group. Data are one representative of two independent biological replicates.

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.